Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Harmony Biosciences Reports Data For Pitolisant In The Treatment Of Excessive Daytime Sleepiness And Fatigue In Myotonic Dystrophy Type 1; The Primary Efficacy Endpoint Was The Change From Baseline To Week 11 In Daytime Sleepiness Scale Score; Secondary Efficacy Endpoints Was Also Greater For Pitolisant Versus Placebo

Author: Benzinga Newsdesk | June 05, 2024 08:26am

Harmony Biosciences (NASDAQ:HRMY) presented data from its Phase 2 signal detection study showing that pitolisant reduced excessive daytime sleepiness (EDS) and fatigue in adults with Myotonic dystrophy Type 1 (DM1).

Posted In: HRMY


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)
07/16/2024 Teladoc Health, Inc. (TDOC)
07/16/2024 Vestis Corporation (VSTS)
07/22/2024 Cambium Networks Corporation (CMBM)
07/22/2024 Biogen Inc. (BIIB)
07/23/2024 Fastly, Inc. (FSLY)
07/29/2024 Enphase Energy, Inc. (ENPH)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)
CORE Finalist